Secondaries announced 10.5.2016

IPOBoutique.Com rates secondary offerings to hit the tape with a ‘BUY’, ‘NEUTRAL’ or ‘AVOID’ rating. Senior Managing Partner Scott Sweet maintains a track record for all secondary’s he’s issued with a ‘BUY’ rating.

Company: Idera Pharmaceuticals
Symbol: IDRA
Price: Last trade $2.61
Trade Date: 10/7
Shares: 19.2 million
Underwriter(s)J.P. Morgan, Goldman Sachs
Rating=Subscription Needed